Are GLP-1 receptor agonists a ‘magic bullet’ for cancer?

IF 66.8 1区医学 Q1 ONCOLOGY

Nature Reviews Cancer Pub Date : 2025-09-10 DOI:10.1038/s41568-025-00874-z

James R. Hebert, E. Angela Murphy, Mary C. Playdon, Liza Makowski, Anna R. Ibele, Ciaran M. Fairman, Lorne J. Hofseth

引用次数: 0

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists are widely prescribed for weight loss. Here, we discuss the need to monitor long-term use for cancer risk and to couple dietary and physical activity recommendations to prevent skeletal muscle atrophy and maintain metabolic health among people using these drugs. Glucagon-like peptide-1 (GLP-1) receptor agonists are widely prescribed for weight loss. Here, Hebert and colleagues discuss the need for long-term studies assessing the impacts of this on muscle mass and nutritional deficiencies, which may influence cancer susceptibility and metabolic health.

查看原文本刊更多论文

GLP-1受体激动剂是治疗癌症的“魔弹”吗？

胰高血糖素样肽-1 （GLP-1）受体激动剂广泛用于减肥。在这里，我们讨论了监测长期使用的癌症风险的必要性，并结合饮食和体育活动建议，以防止骨骼肌萎缩和维持这些药物使用者的代谢健康。胰高血糖素样肽-1 （GLP-1）受体激动剂广泛用于减肥。在这里，Hebert和他的同事讨论了长期研究的必要性，评估这对肌肉质量和营养缺乏的影响，这可能会影响癌症的易感性和代谢健康。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Cancer 医学-肿瘤学

CiteScore

111.90

自引率

0.40%

发文量

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Cancer, a part of the Nature Reviews portfolio of journals, aims to be the premier source of reviews and commentaries for the scientific communities it serves. The correct abbreviation for abstracting and indexing purposes is Nat. Rev. Cancer. The international standard serial numbers (ISSN) for Nature Reviews Cancer are 1474-175X (print) and 1474-1768 (online). Unlike other journals, Nature Reviews Cancer does not have an external editorial board. Instead, all editorial decisions are made by a team of full-time professional editors who are PhD-level scientists. The journal publishes Research Highlights, Comments, Reviews, and Perspectives relevant to cancer researchers, ensuring that the articles reach the widest possible audience due to their broad scope.